phentermine 30 mg efectos secundarios

Obesity: UK 'going down road of America' says David Lammy

Dr Luke Pratsides, Head of Medical at Numan, said obesity is “arguably one of the country’s top public health problems”.

Obesity is linked to diabetes, strokes, heart attacks, and certain cancers.

“Wegovy has been clinically proven to help patients achieve up to a 15 percent reduction in their body weight,” said Dr Pratsides.

Such a reduction in body weight is considered a “game-changing amount” for obese adults.

“Wegovy will be publicly available on the NHS,” Dr Pratsides said, however, does gabapentin help with anxiety the manufacturer, Novo Nordisk, noted its supply will be “constrained for the foreseeable future”.

Don’t miss… Dr Michael Mosley shares easy diet tweak that could help lose weight effectively

As reported in The Independent, Nordisk said: “We will continue to work with healthcare professionals to help ensure that patients with the highest unmet medical need are prioritised.”

To be eligible for Wegovy, also known as semaglutide, patients require a body mass index (BMI) of 30 or higher.

Those who have a BMI of 27 may be considered for treatment, but only if they have one weight-related co-morbidity.

An NHS spokesperson said: “Around 50,000 eligible patients in England could be prescribed Wegovy through NHS specialist weight management services.”

Don’t miss…
‘I’m a professor in respiratory physiology and here’s what I know about Covid'[EXPERT]
‘I thought my leg was itchy because of washing detergent…but it was deadly'[REAL LIFE]
Seven red flag signs of eye health issues to spot in grandchildren[LATEST]

We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info

The National Institute for Care and Excellence (NICE) advised that the drug should only be used for a maximum of two years.

This drug release followed a five-year study by Nordisk – known as the Select trial – that found it could reduce the risk of a heart attack or stroke in obese patients.

The research results, which showed how Wegovy could cut cardiovascular risk by a fifth, was based on 17,604 obese adults, over the age of 45, from across 41 countries.

Dr Pratsides added: “Numan is also excited to be offering [semaglutide] in the coming weeks and will be launching a pre-registration sign-up service for interested men today.

“But we know that medication alone isn’t the solution. That’s why we offer a lifestyle change programme focussing on the key pillars of weight loss.”

The four pillars of weight loss included diet, exercise, sleep and mindset.

Dr Pratsides said: “We offer this alongside access to ongoing clinical support without the need to wait for booked appointments.

“For men who have been struggling with their weight and who want a convenient, timely, private solution, Numan’s online holistic treatment can help them maintain a healthy weight for good.”

Source: Read Full Article